207 related articles for article (PubMed ID: 18292291)
21. CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis.
Boyer O; Saadoun D; Abriol J; Dodille M; Piette JC; Cacoub P; Klatzmann D
Blood; 2004 May; 103(9):3428-30. PubMed ID: 14684420
[TBL] [Abstract][Full Text] [Related]
22. Improvement in psoriasis during rituximab therapy for mixed cryoglobulinemia type II.
Moberg P; Charles JF; Respicio G; Venna SS; Rooney T
Cutis; 2010 Sep; 86(3):133-5. PubMed ID: 21049729
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and risk of rituximab in type II mixed cryoglobulinemia: a significant case report.
Massari M; Catania A; Magnani G
Dig Liver Dis; 2007 Sep; 39 Suppl 1():S134-5. PubMed ID: 17936216
[No Abstract] [Full Text] [Related]
24. B-cell depletion in the treatment of mixed cryoglobulinemia.
Sansonno D; Tucci FA; Montrone M; Troiani L; Sansonno L; Gatti P; Lauletta G
Dig Liver Dis; 2007 Sep; 39 Suppl 1():S116-21. PubMed ID: 17936212
[TBL] [Abstract][Full Text] [Related]
25. [Cryoglobulinemia].
Cacoub P; Sène D; Saadoun D
Rev Med Interne; 2008 Mar; 29(3):200-8. PubMed ID: 18242787
[TBL] [Abstract][Full Text] [Related]
26. Rituximab in cryoglobulinaemic vasculitis, evidence for its effectivity: a case report and review of literature.
Wink F; Houtman PM; Jansen TL
Clin Rheumatol; 2011 Feb; 30(2):293-300. PubMed ID: 21053035
[TBL] [Abstract][Full Text] [Related]
27. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature.
Ferri C; Cacoub P; Mazzaro C; Roccatello D; Scaini P; Sebastiani M; Tavoni A; Zignego AL; De Vita S
Autoimmun Rev; 2011 Nov; 11(1):48-55. PubMed ID: 21821153
[TBL] [Abstract][Full Text] [Related]
28. Serum concentrations of interleukin 1beta, CXCL10, and interferon-gamma in mixed cryoglobulinemia associated with hepatitis C infection.
Antonelli A; Ferri C; Ferrari SM; Ghiri E; Marchi S; Sebastiani M; Fallahi P
J Rheumatol; 2010 Jan; 37(1):91-7. PubMed ID: 19918044
[TBL] [Abstract][Full Text] [Related]
29. The use of monoclonal antibody (rituximab) in the treatment of type II mixed cryoglobulinemia.
Rego TC; Massumoto CM; Batista RS; Moura LH; Soares LM; Gomes AP
Braz J Infect Dis; 2007 Feb; 11(1):174-5. PubMed ID: 17625752
[TBL] [Abstract][Full Text] [Related]
30. Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment.
Basile U; Gragnani L; Piluso A; Gulli F; Urraro T; Dell'Abate MT; Torti E; Stasi C; Monti M; Rapaccini GL; Zignego AL
Liver Int; 2015 Sep; 35(9):2100-7. PubMed ID: 25800731
[TBL] [Abstract][Full Text] [Related]
31. Predominance of type 1 (Th1) cytokine production in the liver of patients with HCV-associated mixed cryoglobulinemia vasculitis.
Saadoun D; Boyer O; Trébeden-Nègre H; Limal N; Bon-Durand V; Andreu M; Klatzmann D; Piette JC; Cacoub P
J Hepatol; 2004 Dec; 41(6):1031-7. PubMed ID: 15582138
[TBL] [Abstract][Full Text] [Related]
32. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Cacoub P; Saadoun D; Limal N; Sene D; Lidove O; Piette JC
Arthritis Rheum; 2005 Mar; 52(3):911-5. PubMed ID: 15751068
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of rituximab in type II mixed cryoglobulinemia.
Zaja F; De Vita S; Mazzaro C; Sacco S; Damiani D; De Marchi G; Michelutti A; Baccarani M; Fanin R; Ferraccioli G
Blood; 2003 May; 101(10):3827-34. PubMed ID: 12560225
[TBL] [Abstract][Full Text] [Related]
34. The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents.
Roccatello D; Sciascia S; Rossi D; Solfietti L; Fenoglio R; Menegatti E; Baldovino S
Oncotarget; 2017 Jun; 8(25):41764-41777. PubMed ID: 28454112
[TBL] [Abstract][Full Text] [Related]
35. Infections in vasculitis.
Guillevin L
Best Pract Res Clin Rheumatol; 2013 Feb; 27(1):19-31. PubMed ID: 23507054
[TBL] [Abstract][Full Text] [Related]
36. Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection.
Benstead TJ; Chalk CH; Parks NE
Cochrane Database Syst Rev; 2014 Dec; (12):CD010404. PubMed ID: 25525951
[TBL] [Abstract][Full Text] [Related]
37. Should rituximab be the rescue therapy for refractory mixed cryoglobulinemia associated with hepatitis C?
Ahmed MS; Wong CF
J Nephrol; 2007; 20(3):350-6. PubMed ID: 17557269
[TBL] [Abstract][Full Text] [Related]
38. Abnormal CD4 + T helper (Th) 1 cells and activated memory B cells are associated with type III asymptomatic mixed cryoglobulinemia in HCV infection.
Kong F; Zhang W; Feng B; Zhang H; Rao H; Wang J; Cong X; Wei L
Virol J; 2015 Jul; 12():100. PubMed ID: 26129991
[TBL] [Abstract][Full Text] [Related]
39. [Current possibilities for treatment for hepatitis C virus-induced cryoglobulinemic vasculitis and B-cell lymphoma].
Ignatova TM; Mukhin NA
Ter Arkh; 2012; 84(11):81-8. PubMed ID: 23252255
[TBL] [Abstract][Full Text] [Related]
40. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study.
Dammacco F; Tucci FA; Lauletta G; Gatti P; De Re V; Conteduca V; Sansonno S; Russi S; Mariggiò MA; Chironna M; Sansonno D
Blood; 2010 Jul; 116(3):343-53. PubMed ID: 20308602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
